Abstract: The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borate or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred.
Type:
Grant
Filed:
April 14, 2011
Date of Patent:
December 4, 2012
Assignee:
Alcon Research, Ltd.
Inventors:
Bhagwati P. Kabra, Masood A. Chowhan, L. Wayne Schneider, Wesley Wehsin Han
Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.
Abstract: The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borat or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred.
Type:
Grant
Filed:
September 20, 2007
Date of Patent:
September 18, 2012
Assignee:
Alcon Research, Ltd.
Inventors:
Bhagwati P. Kabra, Masood A. Chowhan, L. Wayne Schneider, Wesley Wehsin Han
Abstract: Disclosed are ophthalmic device materials having improved light transmission characteristics. The materials contain a combination of certain UV absorbers and blue-light absorbing chromophores.
Abstract: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.
Abstract: Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage.
Abstract: Drug delivery film compositions containing a combination of a water-soluble, film-forming polymers and a fatty acid glyceride or ester are suitable for delivering ophthalmic drugs.
Type:
Grant
Filed:
June 30, 2003
Date of Patent:
December 27, 2011
Assignee:
Novartis AG
Inventors:
Bhagwati P. Kabra, Janet D. Howie, Youqin Tian, David Allen Marsh, Gustav Graff
Abstract: Exemplary embodiments provide a coated intraocular lens that has a lens body with a first refractive index and an anti-reflective coating. The coating covers at least a portion of the lens body and has a second index of refraction that is less than the first index of refraction of the lens body. The anti-reflective coating reduces the intensity of reflections produced from off axis light incident on the lens body by at least a factor of 2.5 times and enhancing light transmission.
Abstract: An exemplary embodiment provides a biocompatible polymer composition suitable for making intraocular lenses, especially posterior chamber phakic lenses, that includes a hydrogel having an equilibrium water content of less than about 55 wt. %. The hydrogel has a refractive index greater than about 1.41 and a sodium ion flux between about 16 to about 20 ?eq-mm/hr/cm2.
Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.
Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity.
Abstract: Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage.
Abstract: Otic compositions are disclosed. The compositions contain an otic drug and a carrier comprising a low molecular weight compound. The compositions do not drain out of the ear after administration.
Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.
Abstract: Disclosed are ophthalmic device materials having improved light transmission characteristics. The materials contain a combination of certain UV absorbers and blue-light absorbing chromophores.
Type:
Grant
Filed:
October 12, 2007
Date of Patent:
April 6, 2010
Assignee:
Alcon, Inc.
Inventors:
David L. Jinkerson, Joseph I. Weinschenk, III, Mutlu Karakelle
Abstract: Disclosed are soft, high refractive index device materials having improved strength. The materials contain a monofunctional or difunctional, acrylate or methacrylate terminated aromatic functional methacrylic or acrylic macromer.
Abstract: An implantable medicament delivery device includes a core body which further includes a single basin or multiple smaller basins for containing a drug or a medicament. Each basin is covered by a screen. The implantable drug delivery device is placed within the body of an animal, and the drug is allowed to diffuse through the holes in the screen to provide treatment of a disease or condition.
Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity.
Abstract: The use of NIPAM polymers to prevent or reduce the formation of protein deposits on the surfaces of medical devices is described. The invention is particularly directed to reduction of the adsorption of proteins on surfaces of contact lenses and other medical prosthetics.